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their untreated female partners. Measures of efﬁcacy included
the Treatment Satisfaction Scale (TSS). The analysis was per-
formed in patients (partners) valid for intent-to-treat plus having
a baseline and post-baseline measurement, followed by subgroup
analysis regarding ED pre-treatment status. Separate analyses of
co-variance adjusting for baseline values and study effects were
conducted to investigate the change in treatment satisfaction in
patients and their partners using the TSS. RESULTS: At base-
line, TSS domain scores (least square means; LS means) were
similar for vardenaﬁl and placebo groups. Vardenaﬁl signiﬁ-
cantly (p < 0.0001) improved the treatment satisfaction for all
domains compared to placebo (LOCF; absolute difference in LS
means for patients and partners): ease of erection (23.4 and
24.9), erectile function satisfaction (36.7 and 32.9), pleasure
from sexual activity (23.0 and 23.7), satisfaction with orgasm
(27.6 and 21.8), conﬁdence to complete sexual activity (28.2 and
32.5), satisfaction with medication (37.4 and 35.6). The effect
of vardenaﬁl on treatment satisfaction in patients who had
received previous treatment with PDE5 inhibitors was even
higher for all domains (absolute difference in LS means between
vardenaﬁl and placebo groups for patients): ease of erection
(25.2), erectile function satisfaction (39.5), pleasure from sexual
activity (25.6), satisfaction with orgasm (29.8), conﬁdence to
complete sexual activity (30.4), satisfaction with medication
(41.3). CONCLUSIONS: Vardenaﬁl signiﬁcantly improved (p <
0.0001) treatment satisfaction in men with ED and their part-
ners. The treatment effect was even higher in patients who had
previously been treated with PDE5 inhibitors.
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OBJECTIVES: Data on prevalence, treatment, and stages of
COPD for Germany are limited. This study aims at investigat-
ing into prevalence and treatment of COPD as well as the 
distribution of COPD stages, frequency of comorbidity, and
exacerbations. METHODS: Claims data from a German sick-
ness fund were used to perform a retrospective cohort study. For
the period of 2001 to 2003 beneﬁciaries 45 years of age or older
were identiﬁed as COPD patients if they had a diagnosis of
emphysema and/or other chronic obstructive pulmonary diseases
(ICD-10 codes J43*, J44*) and/or at least one prescription for a
drug for obstructive airway diseases (ATC R03A*). Comorbid-
ity and exacerbations were identiﬁed according to related diag-
noses and prescriptions. Patients were allocated to COPD stages
by detection of drug prescription patterns as deﬁned by the
GOLD guideline (Pauwels et al., Am J Respir Crit Care Med
2001;163:1256–76). RESULTS: Among 499,550 beneﬁciaries
45 years of age or older 41,100 were identiﬁed as COPD patients
corresponding to a three-year prevalence rate of 8.2%, with rates
of 8.5% in men and 7.9% in women, respectively. Prevalence
rates of 9.3% in total, 9.6% in men, and 9.3% in women, respec-
tively, were estimated for the German resident population 45
years of age or older. For many of the COPD patients only few
speciﬁc drug prescriptions were detected within the three-year
observation period. Sixty-eight percent of patients were allocated
to GOLD stages 0 and 1 (at risk or mild COPD). Exacerbations
were found in 14,513 (35.4%), and comorbidity (mostly car-
diovascular disease) in 63% of patients. CONCLUSION: The
observed COPD prevalence rates are within the range of results
reported in former studies. The low level of treatment with
COPD-related drugs may be an indicator for a low awareness of
COPD among patients as well as among physicians.
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OBJECTIVES: In-patient treatment of community-acquired
pneumonia (CAP) is a generally non-invasive therapy with ﬁnan-
cial burden depending on length of hospitalization. In 2004, the
concept of diagnosis-related groups (DRG) was implemented in
Germany. Objective of this study was to analyse the effect of
DRG implementation on length of hospital stay. METHODS:
Open, prospective observational study conducted in German
hospitals before and during DRG-implementation. Between
October 2002 and July 2003 patients with CAP were enrolled
(cohort A). Between January and October 2005 a second inves-
tigation was conducted (cohort B). No intervention in physi-
cians’ treatment decisions was taken. Diagnostic measures, drug
application, non-medical therapy, nursing time and length of
hospital stay were documented by the treating physicians.
RESULTS: In cohort A 319 patients were documented in 9 hos-
pitals, in cohort B 322 patients in 14 hospitals. Cohort A and B
showed no signiﬁcant differences in demographic data, clinical
condition and severity of CAP classiﬁed according to Fine et al.
88.7% (A) and 92.9% (B) of patients were discharged from hos-
pital due to successful treatment. 11.3% (A) and 7.1% (B) of
patients died. Average length of stay was 10.67 (A) and 10.05
days (B) in peripheral ward (p = 0.229), and 0.79 (A) and 0.75
days (B) in ICU (p = 0.847). Overall length of stay was 11.46
(A) and 10.80 days (B) (p = 0.162). CONCLUSIONS: In this
study the effect of DRG-implementation, measured by length of
hospital stay, was marginal. Between 1994 and 2000 a dramatic
reduction of both length of stay and number of hospital beds
were observed because of a number of new laws aiming at cost
reduction. Therefore, the DRG concept for CAP patients has not
yet led to a signiﬁcantly reduction of length of stay in the hos-
pital sector.
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OBJECTIVE: Roﬂumilast is an oral, once-daily PDE 4 inhibitor
under investigation for COPD and asthma therapy. This study
investigated the cost-effectiveness of Roﬂumilast in patients with
severe to very severe COPD, including the ﬁnancial impact on
the UK health care system. METHODS: The analysis was con-
ducted alongside a randomised, placebo-controlled, multina-
tional trial (M2-112) evaluating the efﬁcacy of roﬂumilast in
terms of lung function and the frequency of moderate and severe
(mod/sev) exacerbations in severe and very severe COPD
patients. COPD-related health care use and absence from work
were recorded. Differences in costs were related to differences in
number of mod/sev exacerbations. Trial wide resource use was
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multiplied with 2004 UK unit cost. A total of 1505 COPD
patients with post FEV1% pred < = 50% were included (roﬂu-
milast 755, placebo 750). 62% were taking inhaled corticos-
teroids. RESULTS: In the total group, COPD-related costs from
a societal perspective were €1635 (roﬂumilast) and €1400
(placebo). From a payer’s perspective this was €1385 and €1253,
respectively. The overall rate of mod/sev COPD exacerbations in
the trial was low and no differences existed between roﬂumilast
(0.96) and placebo (1.06). In a subgroup of patients with very
severe COPD (n = 223), placebo was associated with a high exac-
erbation rate (1.7 exacerbations/patient/year) and roﬂumilast
was associated with 35% fewer exacerbations. This lower exac-
erbation rate was associated with €1001 lower COPD-related
treatment costs. In the subgroup of patients with high health care
resource use prior to the study (n = 549) the roﬂumilast group
showed 0.41 fewer exacerbations per patient per year, which
translated into an ICER of €804 per mod/sev exacerbation
avoided. CONCLUSION: These data suggest that roﬂumilast,
like many newly introduced therapies, increases the overall cost
of therapy for COPD; however, this increase was partly offset by
savings. Furthermore, in this study, roﬂumilast was found to be
cost saving in very severe patients.
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OBJECTIVE: The incidence of community-acquired pneumonia
(CAP) caused by drug resistance has increased dramatically in
recent years. The aim of this analysis was to analyse the impact
of antimicrobial resistance on the cost-effectiveness of different
antibiotic classes (beta-lactams, macrolides, ﬂuoroquinolones) in
patients with CAP in Germany. METHODS: A decision analytic
model was developed for mild-to-moderate CAP outpatient
treatment. Treatment algorithms incorporated follow-up after
treatment failure due to resistance or other reasons. First-line
treatment included moxiﬂoxacin (MXF), beta-lactams (AMX),
or macrolides (ROX); second-line treatment used a different
antimicrobial class. In contrast to existing cost-effectiveness
models in CAP class-speciﬁc resistance proﬁles were included in
the model. This allows for the analysis of the impact of antimi-
crobial resistance on the cost-effectiveness in addition to stan-
dard outcomes like clinical failure, hospitalisation rates and total
costs. Input data were derived from surveillance studies, from lit-
erature and expert opinion. Total costs were estimated using
standard sources and a third-party payer perspective in Germany.
RESULTS: Total cost were €240.60 (MXF), €250.59 (ROX), and
€268.91 (AMX). First-line clinical failure, second-line treatment,
and hospitalisation rates were lower for MXF as compared to
the other treatment options. First-line MXF treatment domi-
nated all other treatments. Antimicrobial resistance accounted
for 53% (AMX), 72% (ROX) and 2% (MXF) of all clinical fail-
ures and 37% (AMX), 56%(ROX) and 1% (MXF) of all hos-
pitalisations. CONCLUSIONS: Antimicrobial resistance has a
signiﬁcant impact on the cost-effectiveness of empirical treat-
ment of CAP. The ﬁrst-line use of moxiﬂoxacin in CAP is a dom-
inant strategy even in a country with a low level of resistance
like Germany.
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OBJECTIVES: Exacerbations are the key drivers of the costs of
chronic obstructive pulmonary disease (COPD). This was the
pilot study of patients with COPD aimed at evaluating direct and
indirect cost of exacerbations under usual clinical practice in
primary and secondary care form societal perspective.
METHOD: It was observational, multicenter study with partic-
ipation of 73 subjects with moderate or severe COPD, deﬁned
according to the current GOLD criteria. Patients presenting at
the selected health care centres were included into the study in
the sequential manner, if they fulﬁlled the inclusion criteria.
Exacerbations were divided into three different severity types
according to Anthonisen N.R. classiﬁcation. The management of
exacerbations followed the usual clinical practice. RESULTS:
The average monthly cost of maintenance therapy of COPD was
ca. PLN 180. The average direct health care cost per exacerba-
tion was PLN 4002 (95% CI = 3537; 4503) and PLN 438 (95%
CI = 326; 570) in secondary and primary care respectively. In
secondary care, the drug acquisition and oxygen therapy cost
represented 18.3% of total direct costs, diagnostic tests costs
accounted for 14.5%, the other hospital care and post-discharge
follow-up visit costs 67%. Costs varied considerably with the
severity of the exacerbation as well as the duration of COPD. In
primary care the cost structure was as follows: diagnostic tests
and medical devices 47.5%, drug acquisition costs 41% and
doctors visits 11.4%. The average indirect costs per exacerba-
tion were PLN 232 and PLN 141, in secondary and primary
respectively. (EUR 1 = PLN 3,85; year 2006). The average
reported number of COPD exacerbations in previous year was
3. CONCLUSION: Exacerbations of COPD are costly. Cost of
exacerbation managed in secondary care is 9-fold higher than in
primary care. Prevention of moderate-to-severe exacerbations,
requiring hospitalization could be very cost-effective strategy.
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OBJECTIVES: In 2004, diagnosis-related groups (DRGs) had
been implemented for the reimbursement of hospitals instead of
daily lump sum. We analysed the effect of DRG-implementation
on direct costs of hospitals on the basis of in-patient treatment
of community-acquired pneumonia (CAP). METHODS: This
open, prospective observational study was divided into two
parts. First part was performed between October 2002 and July
2003, the second in 2005. In-patients suffering from CAP were
enrolled. The perspective of hospital management was applied
for calculation of costs for drug acquisition, non-medical
therapy, diagnostic procedures, hotel and staff. The quantity
aspect of treatment was documented by the physicians. Infor-
mation on the costs per measure was provided by the hospital
controller. RESULTS: In 2002/2003, 319 patients (cohort A)
were documented in 9 hospitals. In 2005, 322 patients (cohort
